Streisand J B, Varvel J R, Stanski D R, Le Maire L, Ashburn M A, Hague B I, Tarver S D, Stanley T H
Department of Anesthesiology, University of Utah School of Medicine, Salt Lake City 84132.
Anesthesiology. 1991 Aug;75(2):223-9. doi: 10.1097/00000542-199108000-00009.
Oral transmucosal fentanyl citrate (OTFC) is a novel, noninvasive dosage form of fentanyl used to provide children and adults with sedation, anxiolysis, and analgesia. In order to determine the bioavailability and absorption of fentanyl from OTFC, 12 volunteers were given intravenous fentanyl citrate or OTFC 15 micrograms/kg on each of two occasions. On a third occasion, the authors assessed oral administration (gastrointestinal absorption) by giving eight of the same volunteers the same dose of a solution of fentanyl citrate to swallow. In each study, arterial blood samples were taken over 24 h for analysis of plasma fentanyl. After intravenous (iv) administration of fentanyl, clearance (mean +/- standard deviation) was 0.67 +/- 0.15 l/min; volume of distribution at steady state was 287 +/- 79 l; and the terminal elimination half-life was 425 +/- 102 min. Peak plasma concentrations of fentanyl were higher (3.0 +/- 1.0 vs. 1.6 +/- 0.6 ng/ml, P = 0.01) and occurred sooner (22 +/- 2.5 vs. 101 +/- 48.8 min, P = 0.003) after OTFC than after oral solution administration. Plasma concentrations of fentanyl after OTFC decreased rapidly, to less than 1.0 ng/ml within 75-135 min after the beginning of administration. Peak absorption rate was greater (11.1 +/- 4.3 vs. 3.6 +/- 2.1 micrograms/min, P = 0.004) and occurred much sooner after OTFC than after oral solution administration (19 +/- 2.6 vs. 87.5 +/- 38.1 min, P = 0.001). Systemic bioavailability was greater after OTFC administration than after the oral solution (0.52 +/- 0.1 vs. 0.32 +/- 0.1, P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
口腔黏膜枸橼酸芬太尼(OTFC)是一种新型的、非侵入性的芬太尼剂型,用于为儿童和成人提供镇静、抗焦虑和镇痛作用。为了确定芬太尼从OTFC中的生物利用度和吸收情况,12名志愿者在两个不同时间分别接受了静脉注射枸橼酸芬太尼或15微克/千克的OTFC。在第三个时间段,作者通过给8名相同的志愿者服用相同剂量的枸橼酸芬太尼溶液来评估口服给药(胃肠道吸收)情况。在每项研究中,在24小时内采集动脉血样以分析血浆芬太尼。静脉注射芬太尼后,清除率(平均值±标准差)为0.67±0.15升/分钟;稳态分布容积为287±79升;终末消除半衰期为425±102分钟。OTFC给药后芬太尼的血浆峰值浓度更高(3.0±1.0对1.6±0.6纳克/毫升,P = 0.01),且出现时间更早(22±2.5对101±48.8分钟,P = 0.003),高于口服溶液给药后。OTFC给药后芬太尼的血浆浓度迅速下降,给药开始后75 - 135分钟内降至低于1.0纳克/毫升。OTFC给药后的峰值吸收率更高(11.1±4.3对3.6±2.1微克/分钟,P = 0.004),且出现时间比口服溶液给药后早得多(19±2.6对87.5±38.1分钟,P = 0.001)。OTFC给药后的全身生物利用度高于口服溶液(0.52±0.1对0.32±0.1,P = 0.01)。(摘要截短至250字)